VMP regimen
Term · Oncology and biomedicine · MLC-T-ONC-017521
A regimen consisting of melphalan, prednisone and bortezomib used for the treatment of plasma cell myeloma.
| Identifier | MLC-T-ONC-017521 |
|---|---|
| Field | Oncology and biomedicine |
| Abbreviation | MPB |
| Synonyms | bortezomib/melphalan/prednisone; melphalan/prednisone/bortezomib; melphalan-prednisone-bortezomib regimen; melphalan/prednisone/Velcade; MPB regimen; Velcade/melphalan/prednisone |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-017521",
"term": "VMP regimen",
"field": "Oncology and biomedicine",
"definition": "A regimen consisting of melphalan, prednisone and bortezomib used for the treatment of plasma cell myeloma.",
"abbreviation": "MPB",
"synonyms": [
"bortezomib/melphalan/prednisone",
"melphalan/prednisone/bortezomib",
"melphalan-prednisone-bortezomib regimen",
"melphalan/prednisone/Velcade",
"MPB regimen",
"Velcade/melphalan/prednisone"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/vmp-regimen/"
}
Record 17,308 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.